Following Positive IIb Study Data, Can 180 Life Sciences Clear The Next Regulatory Hurdle?

MHRA And FDA Need More Information Before Authorization Of Repurposed Adalimumab

180 Life Sciences has found that adalimumab can effectively treat nodule hardness and size in Dupuytren’s disease during a Phase IIb study. But, the company’s CEO Jim Woody tells Generics Bulletin, regulators in the UK and US have requested more information before they will press on with authorization.

Illustration of businessman jumping over hurdle
• Source: Shutterstock

More from Regulation

More from Policy & Regulation